Iovance Biotherapeutics, Inc. (IOVA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$8.79+1.03%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IOVA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 325.0 | 263.5 | 164.1 | 1.2 | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — |
| Cost of Revenues | 167.7 | 173.2 | 124.0 | 1.0 | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 267.7 | 300.3 | 282.3 | 333.2 | 294.8 | 259.0 | 201.7 | 166.0 | 99.8 | 71.6 | 26.9 | 15.5 | 3.8 | 2.2 | 1.7 | 1.8 |
| Operating Income | (301.3) | (403.4) | (395.3) | (460.6) | (398.9) | (342.7) | (261.9) | (206.9) | (128.3) | (92.9) | (53.6) | (27.9) | (12.0) | (22.6) | (8.1) | (21.2) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | — | (0.0) | — | 1.9 | 0.2 |
| Interest & Investment Income | 7.5 | 10.3 | 20.3 | 13.0 | 3.0 | 0.5 | 2.4 | 9.3 | 4.7 | 0.8 | 0.7 | — | — | — | — | — |
| EBT, Incl. Unusual Items | (293.8) | (393.0) | (375.0) | (447.5) | (395.9) | (342.3) | — | — | — | — | — | — | — | — | — | — |
| Income Tax Expense | (4.3) | (2.1) | (2.8) | (3.5) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | (289.5) | (391.0) | (372.2) | (444.0) | (395.9) | (342.3) | (259.6) | (197.6) | (123.6) | (92.1) | (52.9) | (27.7) | (12.0) | (25.4) | (3.3) | (25.7) |
| Per Share | ||||||||||||||||
| Basic EPS | (643.15) | (1.09) | (1.28) | (1.89) | (2.49) | (2.23) | (1.88) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | (643.15) | (1.09) | (1.28) | (1.89) | (2.49) | (2.23) | (1.88) | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 721.85 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 0.5 | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.1 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 0.5 | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.1 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (367.4) | (383.3) | (439.1) | (389.6) | (339.6) | (260.8) | (205.7) | (127.3) | (91.9) | (52.7) | (26.9) | (12.0) | (22.6) | (8.1) | (21.2) |
| EBIT | (301.3) | (403.4) | (395.3) | (460.6) | (398.9) | (342.7) | (261.9) | (206.9) | (128.3) | (92.9) | (53.6) | (27.9) | (12.0) | (22.6) | (8.1) | (21.2) |
| Effective Tax Rate | 1.4% | — | — | 0.8% | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.